Clinical value of combined detection of the serum tumor marker in the diagnosis of breast cancer

Objective To investigate the clinical value of the combined detection of the serum tumor marker(including CA15-3,CYFRA21-1,TSGF and CA19-9) in the diagnosis and treatment of breast cancer.Methods The serum samples of 182 patients with breast cancer were collected,and tumor markers CA15-3,CYFRA21-1,TSGF and CA19-9 were detected with electrochemiluminescence method,and TSGF was detected with chemocolorimetry method.The results were compared with 80 cases of benign breast disease and 50 normal cases.Results The serum levels of CA15-3,TSGF,OPN and CA125 of breast cancer patients were significantly higher than those of the benign breast disease and the normal cases (P ＜ 0.01 ).The sensitivity of CA15-3 to breast cancer was 60.4％ ( 110/182),with a specificity of 90.0％ (45/50),the sensitivity of CYFRA21-1 was 72.5 ( 132/182 ),with a specificity of 86.0％ (43/50),the sensitivity of TSGF was 74.7％ ( 136/182 )with a specificity of 92.0％ (46/50),and the sensitivity of CA19-9 was 36.3％ (66/182),with a specificity of 84.0％ (42/50).The sensitivity of the combination detection of above tumor markers was 91.8％ ( 167/182 ),with a specificity of 84.0％ (42/50).Conclusions CA15-3,CYFRA21-1,TSGF and CA19-9 have certain diagnostic value in breast cancer complementarily,and the combined detection can significantly improve the sensitivity and accuracy of breast cancer diagnosis. Key words: Breast cancer;  Serum tumor marker;  Combined detection;  Value